Pharmafile Logo
Pharmafocus logo
Advanced Search

New Novartis blindness treatment filed in Europe

March 2, 2006
Sales and Marketing AMD, Lucentis, Novartis

Lucentis, a new treatment for neovascular age-related macular degeneration or ‘wet AMD’ has been submitted by Novartis to the European …

News

Herceptin challenges put patient safety at risk, says survey

March 2, 2006

NHS managers have warned that the sidelining of the normal regulatory process for new medicines will put patient safety at …

News

GSK launches Europe’s first rotavirus vaccine

March 1, 2006
Sales and Marketing

GlaxoSmithKline has launched Rotarix in Europe, the first ever marketed vaccine against rotavirus gastroenteritis, a common but potentially lethal condition …

News

Bioenvision’s leukaemia treatment gains positive opinion

March 1, 2006
Sales and Marketing

Bioenvision has received a positive opinion from the European Medicines Agency for Evoltra (clofarabine), the first drug specifically developed for …

News

Erbitux closer to head and neck cancer approval

March 1, 2006
Sales and Marketing

Merck KGaA's targeted cancer treatment Erbitux has moved a step closer to receiving EU approval to extend its licence to …

News

Novartis files new Hepatitis B treatment in Europe

February 28, 2006
Sales and Marketing

Novartis has filed its new hepatitis B treatment telbivudine in the European Union, and says it represents a potential new …

News

ABPI chief calls for ‘new rules of engagement’

February 23, 2006
Sales and Marketing

UK pharmaceutical industry leader Richard Barker has called for a fundamental rethink in the way the industry and the NHS …

News

Gene silencing technology to be used in war against bird flu

February 23, 2006
Sales and Marketing

Cutting edge technology will be used develop new drugs to treat dangerous strains of influenza, including the threat of a …

News

Wyeth to open clinical trial ‘Super Centres’

February 23, 2006
Research and Development

Wyeth has unveiled plans to streamline its drug development operations by opening a network of clinical trial 'Super Centres' around …

News

Pfizer’s new blood infection drug Eraxis approved

February 23, 2006
Research and Development

Eraxis, a new treatment for potentially life-threatening fungal infections has been approved in the US.Pfizer's new antifungal is licensed to …

News

Sanofi’s wonder drug in limbo after regulator’s rejection

February 23, 2006
Sales and Marketing

The future of Sanofi-Aventis' Acomplia is in serious doubt after regulators demanded more data for its use in weight loss, …

News

Pegasys recommended as front line hepatitis B treatment

February 23, 2006
Sales and Marketing

Roche's Pegasys is set to be used more widely in England and Wales to treat hepatitis B following the release …

News

Tysabri trials restart after safety scare

February 20, 2006
Research and Development

Clinical trials of Tysabri, the troubled multiple sclerosis treatment, are to begin again in the US after the FDA gave …

News

Avastin trial recruitment suspended after patient deaths

February 16, 2006
Research and Development

Roche has stopped recruiting colon cancer patients who have undergone surgery to a trial of Avastin after four suddenly died.The …

News

WHO calls for action on counterfeits

February 16, 2006
Manufacturing and Production

The World Health Organisation has called for 'immediate concrete' action against counterfeit medicines, which it says pose serious and sometimes …

News

Woman loses Herceptin court case

February 16, 2006

Breast cancer patient Ann Marie Rogers has lost her court battle to be prescribed Herceptin on the NHS, in what …

News

Merck files novel diabetes drug Januvia

February 16, 2006
Sales and Marketing

Merck has filed an innovative new diabetes treatment with the US regulator, and hopes the drug could be one of …

News

Working with NHS priorities

February 16, 2006

Patients, health professionals and even some politicians have said it, now chief medical officer Nigel Crisp has confirmed it in …

Feature

Safety scare spells the end for Exanta

February 15, 2006
Sales and Marketing

AstraZeneca is to abandon its novel anti-blood clotting drug Exanta after concerns emerged about its long-term safety.Just two years ago, …

News

Wyeth joins search for promising TLR drugs

February 15, 2006
Research and Development

A new collaboration between Wyeth and an Irish biotech company is to investigate the potential of 'toll like receptors', which …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026